查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
鐮狀細胞病治療市場與 COVID-19 影響分析，按疾病、治療、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1335286

鐮狀細胞病治療市場與 COVID-19 影響分析，按疾病、治療、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Sickle Cell Disease Treatment Market with COVID-19 Impact Analysis, By Disease, By Treatment, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年鐮狀細胞病治療市場規模為 10.107 億美元，2023 年至 2030 年年複合成長率為 30.8%。

鐮狀細胞病治療市場-市場動態：

  • 新型藥物的創新推動了市場的成長。
  • 英國發現了 20 年來首個治療鐮狀細胞病的新療法。 Crizanlizumab 是諾華公司生產的一種藥物，被稱為“一種創新療法”。據英國廣播公司報導，它被注射到靜脈中，可以單獨使用，也可以與定期輸血和常規醫療護理結合使用。在一項研究中，使用 crizanlizumab 的患者平均每年經歷 1.6 次鐮狀細胞危象，低於正常情況下每年近 3 次。一種名為 crizanlizumab 的藥物用於降低 16 歲及以上鐮狀細胞性貧血患者血管閉塞危象的發生率。由於這些創造性的突破性治療，鐮狀細胞病治療市場正在擴大。

鐮狀細胞病治療市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，預計全球鐮狀細胞病治療市場在預測期內（2023-2030）每年將以 30.8% 左右的年複合成長率成長
  • 由於鐮狀細胞貧血病的高發病率，鐮狀細胞病治療行業預計將以顯著的速度成長
  • 根據該疾病，鐮狀細胞貧血症預計在預測期內將以最高年複合成長率成長
  • 根據治療方法，輸血領域預計將在預測期內佔據最大的市場佔有率
  • 從地區來看，預計北美將在預測期內主導市場

鐮狀細胞病治療市場-細分分析：

  • 全球鐮狀細胞病治療市場根據疾病、治療和區域進行細分。
  • 根據疾病，全球鐮狀細胞病治療市場分為鐮狀細胞貧血症、鐮狀血紅蛋白c病、鐮狀BETA地中海貧血等。鐮狀細胞貧血症領域預計在預測期內將以最高的年複合成長率成長。這種擴張是由於基因突變導致鐮狀細胞性貧血患者數量增加的結果。 11 號染色體上發現的血紅蛋白-BETA 基因突變會導致鐮狀細胞病。由於血紅蛋白缺陷，鐮狀細胞性貧血中的紅細胞堅硬、粘稠且畸形。遺傳性鐮狀細胞性貧血的流行正在加速這個市場的擴張。
  • 根據治療，全球市場分為輸血、藥物治療、骨髓移植。預計輸血領域將在預測期內佔據最大的市場佔有率。鐮狀細胞病治療中大量使用輸血是這一上升的原因。急性胸部症候群 (ACS) 可通過簡單的濃縮紅細胞輸注 (ST) 和自動紅細胞交換 (RCE) 進行治療。鐮狀細胞病患者通常患有中風，擴大使用輸血來治療中風，這推動了該市場的擴張。

鐮狀細胞病治療市場-地理洞察：

從地域上看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內主導市場。該地區市場收入的成長主要得益於鐮狀細胞病治療的重大進步和治療方案的廣泛普及。該地區高水平的可支配收入也是市場收入擴大的主要推動力。由於政府援助不斷增加，美國市場的收入佔有率最高。此外，當地市場參與者正在聯手進行收購，以使其產品多樣化並建立全球影響力。例如，2022 年，輝瑞公司 (Pfizer Inc.) 和 Global Blood Therapeutics, Inc. 達成一項協議，最終將增加血液學產品組合。

鐮狀細胞病治療市場-競爭格局：

該市場的主要參與者包括Medunik USA、Bristol Myers Squibb Co.、Emmaus Medical Inc.、Addmedica、Novartis AG、Global Blood Therapeutics Inc.、Sanofi SA、Bluebird Biotechnology、Pfizer Inc.、Aruvant Sciences Inc.、Glycomimetics Inc. 。 、Editas Medicine Inc. 和 CRISPR Therapeutic。

最近的發展：

2022 年 2 月，Global Blood Therapeutics Inc. 獲准銷售 Oxbryta，用於治療成人和 12 歲及以上兒童的鐮狀細胞病 (SCD) 相關溶血性貧血，作為單一療法或與羥基脲聯合治療。

該研究的主要特點：

  • 這項關於鐮狀細胞病治療市場的擬議研究提供了市場規模（百萬美元）、年複合成長率（CAGR%）和預測估計（2023-2030），以 2022 年為基準年
  • 該報告為客戶提供有關鐮狀細胞病治療市場的最新趨勢見解。
  • 該研究報告闡明了不同細分市場/國家的潛在成長機會，並解釋了鐮狀細胞病治療市場有吸引力的投資主張矩陣
  • 總體報告確定了鐮狀細胞病治療市場的新投資機會、現有參與者面臨的挑戰以及維持鐮狀細胞病治療市場的成長因素
  • COVID-19 對鐮狀細胞病治療市場規模、預測、年複合成長率和市場動態的影響將在研究範圍下詳細討論。還將詳細介紹新冠疫情后鐮狀細胞病治療市場的情況。
  • 為了讓本報告的用戶全面了解鐮狀細胞病治療市場，我們還包括鐮狀細胞病治療市場的競爭格局和關鍵創新者分析。
  • 該研究包括成長前景映射分析，其中所有行業細分都根據其市場規模、成長率和吸引力進行基準測試。
  • 該報告提供了主要市場參與者的詳細公司概況，這將幫助用戶了解鐮狀細胞病治療市場參與者的財務資訊和戰略舉措。
  • 此外，報告還公佈了全球和區域市場主要參與者的重要收購和合併、合作和合資、新產品推出、研發、區域擴張。
  • 全球鐮狀細胞病治療市場報告主要面向該行業的各個利益相關者，包括供應商、投資者、新進入者、分銷商和財務分析師

目錄

第一章：鐮狀細胞病治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按疾病分類的鐮狀細胞病治療市場片段
    • 鐮狀細胞病治療市場片段（按治療）
    • 按國家/地區分類的鐮狀細胞病治療市場片段
    • 按地區分類的鐮狀細胞病治療市場片段
  • 競爭洞察

第 3 章：鐮狀細胞病治療主要市場趨勢

  • 鐮狀細胞病治療市場促進因素
    • 市場促進因素的影響分析
  • 鐮狀細胞病治療市場限制
    • 市場限制影響分析
  • 鐮狀細胞病治療市場機會
  • 鐮狀細胞病治療市場未來趨勢

第 4 章：鐮狀細胞病治療行業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：鐮狀細胞病治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的細分市場
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：鐮狀細胞病治療市場格局

  • 2022 年鐮狀細胞病治療市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：鐮狀細胞病治療市場 - 按疾病分類

  • 概述
    • 按疾病分類的細分市場佔有率分析
    • 鐮狀細胞性貧血
    • 鐮狀血紅蛋白C病
    • 鐮狀BETA地中海貧血
    • 其他

第 8 章：鐮狀細胞病治療市場 - 按治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 輸血
    • 藥物治療
    • 骨髓移植

第 9 章：鐮狀細胞病治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美
    • 概述
    • 北美鐮狀細胞病治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按疾病）
    • 北美市場規模和預測（按不同處理方式）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲鐮狀細胞病治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按疾病）
    • 歐洲市場規模和預測（按處理方式）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區鐮狀細胞病治療主要製造商
    • 亞太地區市場規模和預測（按國家）
    • 亞太地區市場規模和預測（按疾病）
    • 亞太地區市場規模和預測（按不同處理方式）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲鐮狀細胞病治療主要製造商
    • 拉丁美洲市場規模和預測（按國家）
    • 拉丁美洲市場規模和預測（按疾病）
    • 拉丁美洲市場規模和預測（按不同處理方式）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲鐮狀細胞病治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按疾病）
    • 中東和非洲市場規模及預測（按不同處理方式）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 火雞
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 10 章：主要供應商分析 - 鐮狀細胞病治療行業

  • 競爭儀表板
  • 公司簡介
    • Medunik USA
    • Bristol Myers Squibb Co.
    • Emmaus Medical Inc.
    • Addmedica
    • Novartis AG
    • Global Blood Therapeutics Inc.
    • Sanofi SA
    • Bluebird Biotechnology
    • Pfizer Inc.
    • Aruvant Sciences Inc.
    • Glycomimetics Inc.
    • Editas Medicine Inc.
    • CRISPR Therapeutic

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯繫我們
Product Code: ANV1577

REPORT HIGHLIGHT

Sickle Cell Disease Treatment Market size was valued at USD 1,010.7 Million in 2022, expanding at a CAGR of 30.8% from 2023 to 2030.

Hemoglobin, a protein that transports oxygen throughout the body, is impacted by sickle cell disease (SCD), a hereditary red blood cell (RBC) problem. Numerous consequences are brought on by it, including acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). Currently, doctors frequently recommend bone marrow and blood transplants to treat SCD. It entails removing the damaged bone marrow and replacing it with healthy bone marrow obtained from a donor. As they can lessen particular symptoms and extend patients' lives, other efficient therapies including pharmaceuticals and blood transfusions are also being used.

Sickle Cell Disease Treatment Market- Market Dynamics:

  • Innovation in novel medication drives the market growth.
  • The first new treatment for sickle cell disease in 20 years has been discovered in the United Kingdom. Crizanlizumab, a drug produced by Novartis, has been referred to be "an innovative treatment." According to the BBC, it is injected into a vein and can be used alone or in conjunction with regular blood transfusions and conventional medical care. In a study, patients using crizanlizumab experienced a sickle-cell crisis 1.6 times year on average, down from nearly three times annually in the norm. A drug called crizanlizumab is used to reduce the incidence of vaso-occlusive crises in sickle cell anemia patients aged 16 and older. The Sickle Cell Disease Treatment Market is expanding as a result of these inventive breakthrough treatments.

Sickle Cell Disease Treatment Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Sickle Cell Disease Treatment market is estimated to grow annually at a CAGR of around 30.8% over the forecast period (2023-2030)
  • The Sickle Cell Disease Treatment industry is projected to grow at a significant rate owing to the high incidence of sickle cell anemia disease
  • Based on the disease, the sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period
  • Based on the treatment, the blood transfusion segment is expected to capture the largest market share over the forecast period
  • Based on region, North America is expected to dominate the market over the forecast period

Sickle Cell Disease Treatment Market- Segmentation Analysis:

  • The Global Sickle Cell Disease Treatment Market is segmented based on disease, treatment, and Region.
  • Based on disease, the global Sickle Cell Disease Treatment market is segmented into sickle cell anaemia, sickle haemoglobin c disease, sickle beta thalassemia, others. The sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period. This expansion is the result of an increase in sickle cell anemia patients brought on by a gene mutation. A mutation in the haemoglobin-Beta gene found on chromosome 11 causes sickle cell disease. Red blood cells in sickle cell anemia are hard, sticky, and malformed as a result of the defective hemoglobin. The prevalence of inheriting sickle cell anemia is accelerating this market's expansion.
  • Based on treatment, the global market is segmented into blood transfusion, pharmacotherapy, bone marrow transplant. The blood transfusion segment is expected to capture the largest market share over the forecast period. The massive use of blood transfusion in the treatment of sickle cell disease is the cause of this rise. Acute chest syndrome (ACS) is treated with both simple transfusion (ST) of packed red blood cells and automated red cell exchange (RCE). The increasing use of blood transfusions in the treatment of stroke, which sickle cell disease patients commonly have, is fueling this market's expansion.

Sickle Cell Disease Treatment Market- Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. The region's market revenue growth is primarily being driven by significant advancements in the treatment of sickle cell disease and widespread accessibility to treatment options. The high level of disposable income in this region is also a major driver of the expansion of market revenue. The highest revenue share came from the U.S. market as a result of rising government assistance. Additionally, local market players are joining forces and making acquisitions to diversify their product offerings and establish a worldwide presence. For instance, in 2022, Pfizer Inc. and Global Blood Therapeutics, Inc. reached a deal that will ultimately increase the hematology product portfolio.

Sickle Cell Disease Treatment Market- Competitive Landscape:

The key players operating in the market are Medunik USA, Bristol Myers Squibb Co., Emmaus Medical Inc., Addmedica, Novartis AG, Global Blood Therapeutics Inc, Sanofi SA, Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc. and CRISPR Therapeutic.

Recent Developments:

In February 2022, Global Blood Therapeutics Inc. was granted permission to sell Oxbryta for the treatment of sickle cell disease (SCD)-related hemolytic anemia in adults and children 12 years of age and older as a monotherapy or in combination with hydroxycarbamide.

Key features of the study:

  • This proposed research study on Sickle Cell Disease Treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Sickle Cell Disease Treatment market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Sickle Cell Disease Treatment market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Sickle Cell Disease Treatment market
  • Impact of COVID-19 on Sickle Cell Disease Treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Sickle Cell Disease Treatment market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Sickle Cell Disease Treatment market, we have also included competitive landscape and key innovator analysis for the Sickle Cell Disease Treatment market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Sickle Cell Disease Treatment market.
  • In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Sickle Cell Disease Treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET KEY PLAYERS

  • Medunik USA
  • Bristol Myers Squibb Co.
  • Emmaus Medical Inc.
  • Addmedica
  • Novartis AG
  • Global Blood Therapeutics Inc.
  • Sanofi SA
  • Bluebird Biotechnology
  • Pfizer Inc.
  • Aruvant Sciences Inc.
  • Glycomimetics Inc.
  • Editas Medicine Inc.
  • CRISPR Therapeutic

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE

  • Sickle Cell Anaemia
  • Sickle Haemoglobin C Disease
  • Sickle Beta Thalassemia
  • Others

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TREATMENT

  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sickle Cell Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sickle Cell Disease Treatment Market Snippet by Disease
    • 2.1.2. Sickle Cell Disease Treatment Market Snippet by Treatment
    • 2.1.3. Sickle Cell Disease Treatment Market Snippet by Country
    • 2.1.4. Sickle Cell Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Sickle Cell Disease Treatment Key Market Trends

  • 3.1. Sickle Cell Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sickle Cell Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sickle Cell Disease Treatment Market Opportunities
  • 3.4. Sickle Cell Disease Treatment Market Future Trends

4. Sickle Cell Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sickle Cell Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Sickle Cell Disease Treatment Market Landscape

  • 6.1. Sickle Cell Disease Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sickle Cell Disease Treatment Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2022 & 2030 (%)
    • 7.1.2. Sickle Cell Anaemia
    • 7.1.3. Sickle Haemoglobin C Disease
    • 7.1.4. Sickle Beta Thalassemia
    • 7.1.5. Others

8. Sickle Cell Disease Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 8.1.2. Blood Transfusion
    • 8.1.3. Pharmacotherapy
    • 8.1.4. Bone Marrow Transplant

9. Sickle Cell Disease Treatment Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Sickle Cell Disease Treatment Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Sickle Cell Disease Treatment Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Sickle Cell Disease Treatment Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Sickle Cell Disease Treatment Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Sickle Cell Disease Treatment Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Sickle Cell Disease Treatment Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Medunik USA
    • 10.2.2. Bristol Myers Squibb Co.
    • 10.2.3. Emmaus Medical Inc.
    • 10.2.4. Addmedica
    • 10.2.5. Novartis AG
    • 10.2.6. Global Blood Therapeutics Inc.
    • 10.2.7. Sanofi SA
    • 10.2.8. Bluebird Biotechnology
    • 10.2.9. Pfizer Inc.
    • 10.2.10. Aruvant Sciences Inc.
    • 10.2.11. Glycomimetics Inc.
    • 10.2.12. Editas Medicine Inc.
    • 10.2.13. CRISPR Therapeutic

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Sickle Cell Disease Treatment Market: Disease Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Disease
  • TABLE Global Sickle Cell Disease Treatment Market, by Disease 2018-2030 (USD Million)
  • TABLE Sickle Cell Disease Treatment Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Sickle Cell Disease Treatment Market, by Treatment 2018-2030 (USD Million)
  • TABLE Sickle Cell Disease Treatment Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Sickle Cell Disease Treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Sickle Cell Disease Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Sickle Cell Disease Treatment Market, by Disease, 2018-2030 (USD Million)
  • TABLE North America Sickle Cell Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Sickle Cell Disease Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Sickle Cell Disease Treatment Market, by Disease, 2018-2030 (USD Million)
  • TABLE Europe Sickle Cell Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Sickle Cell Disease Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Sickle Cell Disease Treatment Market, by Disease, 2018-2030 (USD Million)
  • TABLE Asia Pacific Sickle Cell Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Sickle Cell Disease Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Sickle Cell Disease Treatment Market, by Disease, 2018-2030 (USD Million)
  • TABLE Latin America Sickle Cell Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Sickle Cell Disease Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Sickle Cell Disease Treatment Market, by Disease, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Sickle Cell Disease Treatment Market, by Treatment, 2018-2030 (USD Million)